We have shown that the combination of the β emitting anti-CD37 RIT 177Lu-NNV003 and the PARP inhibitor olaparib was robustly synergistic in four of seven NHL cell lines, conditionally synergistic in two and antagonistic in one. Here, PARP1 is linked to non-Hodgkin lymphoma.